摘要 : Therapy outcomes older adults with immune checkpoint inhibitor therapy is particularly important since, they are underrepresented in most trials and age-related factors may have an influence on the immune system. This is a retrosp... 展开 Therapy outcomes older adults with immune checkpoint inhibitor therapy is particularly important since, they are underrepresented in most trials and age-related factors may have an influence on the immune system. This is a retrospective review from a single center on the clinical and radiological outcome of therapy of metastatic NSCLC in patients >70 years of age treated with anti-PD-(L)1 monotherapy. Introduction: As a result of the approval of several immune checkpoint inhibitors (ICIs) for the treatment of non-small cell lung cancer (NSCLC), many older adults are being treated with ICIs. Older adults are underrepresented in most pharmaceutical clinical trials. Therapy outcomes in this population with ICIs is particularly important since, age related factors may have an influence on the immune system. Methods: We utilized the MD Anderson Cancer Center Gemini Team's Lung Cancer Database to retrospectively study patients >= 70 years of age with advanced NSCLC treated with anti-PD-(L)1 monotherapy to look at the clinical outcomes. Results: 179 patients met the inclusion criteria for this retrospective analysis. There were 106 men and 73 women. The median age of the cohort was 74.9 years, and overall survival was 20.6 months. 276% of all patients had an objective response to therapy. In 33 patients who had radiological progression, treatment continued beyond progression due to clinical benefit. In this group, 6 patients had subsequent improvement in radiologic assessment. Age groups were not significantly associated with differences in clinical outcomes. Conclusions: This study suggests that anti-PD-(L)1 monotherapy is effective and well tolerated among older adults with advanced NSCLC. While pseudoprogression is rare, treatment beyond progression may provide clinical benefit in a subset o patients and warrants further investigation. (C) 2022 Elsevier Inc. All rights reserved. 收起